Growth Modulation of Diabetic Factors and Antidiabetic Drugs on Prostate Cancer Cell Lines

10.4077/CJP.2016.BAE368

Shiaw-Wen Chien；Dong-Yih Kuo；Jiuan-Miaw Liao；Paulus S. Wang；Ching-Han Yu

antidiabetic drugs ； diabetes mellitus ； IGF-1 ； insulin ； prostate cancer

The Chinese Journal of Physiology

59卷2期（2016 / 04 / 30）

109 - 118

英文

Risk factors for prostate cancer (PCa) include age, hormones, race, family history and diet. Recently, epidemiologic evidence has indicated that history of diabetes mellitus (DM) is inversely associated with risk of PCa. However, epidemiological investigations have yielded inconsistent results. Hence, the exact mechanism of DM-induced reduction in the incidence of PCa has yet to be fully elucidated. The aim of this study was to investigate the effects of DM factors, including glucose, insulin and insulin-like growth factor-1 (IGF-1), on the proliferation of PCa cell lines in vitro. Cell proliferation and expression of hormone receptors was examined in MTT assay and Western blot analysis, respectively. The results showed that DM factors did not affect the viability of androgen receptor (AR)-expressing PCa cell lines. However, cell proliferation increased after treatment with DM factors in androgen-independent PCa cell lines. On PCa tissue arrays, intensities of total AR and nuclear IGF-1R were higher in malignant tissues than in normal prostate glands. In terms of hormonal receptors, androgen-dependent LNCaP cells treated with insulin and IGF-1 in a low-serum medium showed decreased expression of insulin receptor beta (IRβ) and elevated expression of IGF-1 receptor beta (IGF-1Rβ). Moreover, expression of AR was upregulated after insulin and IGF-1 treatment in LNCaP cells, but not in the other PCa cell lines. Most of the studied antidiabetic drugs promoted the viability of PCa cells. However, metformin decreased the viability of AR-expressing PCa cells. These results suggest that diabetic factors modify the expression of AR, IR and IGF-1R to increase cancer cell proliferation. Moreover, the growth suppressing effects of metformin on PCa may be via the regulation of the AR signaling pathway.

1. Aleksic, T.,Chitnis, M.M.,Perestenko, O.V.,Gao, S.,Thomas, P.H.,Turner, G.D.,Protheroe, A.S.,Howarth, M.,Macaulay, V.M.(2010).Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells.Cancer Res.,70,6412-6419.
2. Bonovas, S.,Filioussi, K.,Tsantes, A.(2004).Diabetes mellitus and risk of prostate cancer: a meta-analysis.Diabetologia,47,1071-1078.
3. Boucher, J.,Tseng, Y.H.,Kahn, C.R.(2010).Insulin and insulin-like growth factor-1 receptors act as ligand-specific amplitude modulators of a common pathway regulating gene transcription.J. Biol. Chem.,285,17235-17245.
4. Buchanan, G.,Irvine, R.A.,Coetzee, G.A.,Tilley, W.D.(2001).Contribution of the androgen receptor to prostate cancer predisposition and progression.Cancer Metastasis Rev.,20,207-223.
5. Cai, C.,He, H.H.,Chen, S.,Coleman, I.,Wang, H.,Fang, Z.,Chen, S.,Nelson, P.S.,Liu, X.S.,Brown, M.,Balk, S.P.(2011).Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.Cancer Cell,20,457-471.
6. Deng, H.,Lin, Y.,Badin, M.,Vasilcanu, D.,Strömberg, T.,Jernberg-Wiklund, H.,Sehat, B.,Larsson, O.(2011).Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9.Biochem. Biophys. Res. Commun.,404,667-671.
7. Evans, J.M.,Donnelly, L.A.,Emslie-Smith, A.M.,Alessi, D.R.,Morris, A.D.(2005).Metformin and reduced risk of cancer in diabetic patients.Brit. Med. J.,330,1304-1305.
8. Feldman, B.J.,Feldman, D.(2001).The development of androgenindependent prostate cancer.Nat. Rev. Cancer,1,34-45.
9. Genua, M.,Pandini, G.,Sisci, D.,Castoria, G.,Maggiolini, M.,Vigneri, R.,Belfiore, A.(2009).Role of cyclic AMP response elementbinding protein in insulin-like growth factor-I receptor up-regulation by sex steroids in prostate cancer cells.Cancer Res.,69,7270-7277.
10. Giovannucci, E.,Michaud, D.(2007).The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas.Gastroenterology,132,2208-2225.
11. Grönberg, H.(2003).Prostate cancer epidemiology.Lancet,361,859-864.
12. Han, M.,Partin, A.W.,Piantadosi, S.,Epstein, J.I.,Walsh, P.C.(2001).Era specific biochemical recurrence free survival following radical prostatectomy for clinically localized prostate cancer.J. Urol.,166,416-419.
13. Hemminki, K.,Li, X.,Sundquist, J.,Sundquist, K.(2010).Risk of cancer following hospitalization for type 2 diabetes.Oncologist,15,548-555.
14. Hjartåker, A.,Langseth, H.,Weiderpass, E.(2008).Obesity and diabetes epidemics: cancer repercussions.Adv. Exp. Med. Biol.,630,72-93.
15. Hsieh, M.C.,Lee, T.C.,Cheng, S.M.,Tu, S.T.,Yen, M.H.,Tseng, C.H.(2012).The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese.Exp. Diabetes Res.,2012,413782.
16. Kasper, J.S.,Giovannucci, E.(2006).A meta-analysis of diabetes mellitus and the risk of prostate cancer.Cancer Epidemiol. Biomarkers Prev.,15,2056-2062.
17. Kim, H.S.,Presti, J.C. Jr.,Aronson, W.J.,Terris, M.K.,Kane, C.J.,Amling, C.L.,Freedland, S.J.(2010).Glycemic control and prostate cancer progression: result from SRARCH database.Prostate,70,1540-1546.
18. Lee, S.Y.,Song, C.H.,Xie, Y.B.,Jung, C.,Choi, H.S.,Lee, K.(2014).SMILE upregulated by metformin inhibits the function of androgen receptor in prostate cancer cells.Cancer Lett.,354,390-397.
19. Leone, A.,Di Gennaro, E.,Bruzzese, F.,Avallone, A.,Budillon, A.(2014).New perspective for an old antidiabetic drug: metformin as anticancer agent.Cancer Treat. Res.,159,355-376.
20. Long, X.J.,Lin, S.,Sun, Y.N.,Zheng, Z.F.(2012).Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis.Asian Pac. J. Cancer Prev.,13,4097-4100.
21. Lubik, A.A.,Gunter, J.H.,Hendy, S.C.,Locke, J.A.,Adomat, H.H.,Thompson, V.,Herington, A.,Gleave, M.E.,Pollak, M.,Nelson, C.C(2011).Insulin increases de novo steroidogenesis in prostate cancer cells.Cancer Res.,71,5754-5764.
22. Müller, H.,Raum, E.,Rothenbacher, D.,Stegmaier, C.,Brenner, H.(2009).Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostatespecific antigen cutoff value?.Cancer Epidemiol. Biomarkers Prev.,18,1350-1356.
23. Olefsky, J.M.,Kolterman, O.G.(1981).Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes.Am. J. Med.,70,151-168.
24. Pierce, B.L.,Ahsan, H.(2010).Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk.Hum. Hered.,69,193-201.
25. Rodriguez, C.,Patel, A.V.,Mondul, A.M.,Jacobs, E.J.,Thun, M.J.,Calle, E.E.(2005).Diabetes and risk of prostate cancer in a prospective cohort of US men.Am. J. Epidemiol.,161,147-152.
26. Ryan, C.J.,Zavodovskaya, M.,Youngren, J.F.,Campbell, M.,Diamond, M.,Jones, J.,Shiry, L.,Allan, G.,Maddux, B.A.,Goldfine, I.D.(2008).Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.Prostate,68,1232-1240.
27. Sayeed, A.,Alam, N.,Trerotola, M.,Languino, L.R.(2012).Insulin-like growth factor 1 stimulation of androgen receptor activity requires b1A integrins.J. Cell. Physiol.,227,751-758.
28. Siegel, R.L.,Miller, K.D.,Jemal, A.(2015).Cancer statistics.CA Cancer J. Clin.,65,5-29.
29. Singh, P.,Alex, J.M.,Bast, F.(2014).Insulin receptor (IR) and insulinlike growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.Med. Oncol.,31,805.
30. Sung, J.F.C.,Lin, R.S.,Pu, Y.S.,Chen, Y.C.,Chang, H.C.,Lai, M.K.(1999).Risk factor for prostate carcinoma in Taiwan: a case-control study in a Chinese population.Cancer,86,484-491.
31. Takeuchi, A.,Shiota, M.,Beraldi, E.,Thaper, D.,Takahara, K.,Ibuki, N.,Pollak, M.,Cox, M.E.,Naito, S.,Gleave, M.E.,Zoubeidi, A.(2014).Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth.Mol. Cell. Endocrinol.,384,117-125.
32. Trapman, J.,Ris-Stalpers, C.,van der Korput, J.A.,Kuiper, G.G.,Faber, P.W.,Romijn, J.C.,Mulder, E.,Brinkmann, A.O.(1990).The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines.J. Steroid Biochem. Mol. Biol.,37,837-842.
33. Tseng, C.H.(2011).Diabetes and risk of prostate cancer: a study using the National Health Insurance.Diabetes Care,34,616-621.
34. Tseng, C.H.(2012).Insulin use is not significantly predictive for prostate cancer mortality in diabetic patients: a 12-year follow-up study.BJU Int.,110,668-673.
35. Tseng, C.H.(2014).Human insulin does not increase prostate cancer risk in Taiwanese.Clin. Genitourin. Cancer,12,e7-e12.
36. Tseng, C.H.(2014).Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.Eur. J. Cancer,50,2831-2837.
37. Tseng, C.H.(2011).Prostate cancer mortality in Taiwanese men: increasing age-standardized trend in general population and increased risk in diabetic men.Ann. Med.,43,142-150.
38. Ueda, T.,Bruchovsky, N.,Sadar, M.D.(2002).Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways.J. Biol. Chem.,277,7076-7085.
39. van Gaal, J.C.,Roeffen, M.H.,Flucke, U.E.,van der Laak, J.A.,van der Heijden, G.,de Bont, E.S.,Suurmeijer, A.J.,Versleijen-Jonkers, Y.M.,van der Graaf, W.T.(2013).Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.Eur. J. Cancer,49,3462-3470.
40. Vigneri, P.,Frasca, F.,Sciacca, L.,Pandini, G.,Vigneri, R.(2009).Diabetes and cancer.Endocr. Relat. Cancer,16,1103-1123.
41. Waters, K.M.,Henderson, B.E.,Stram, D.O.,Wan, P.,Kolonel, L.N.,Haiman, C.A.(2009).Association of diabetes with prostate cancer risk in the multiethnic cohort.Am. J. Epidemiol.,169,937-945.
42. Wu, J.D.,Haugk, K.,Woodke, L.,Nelson, P.,Coleman, I.,Plymate, S.R.(2006).Interaction of IGF signaling and androgen receptor in prostate cancer progression.J. Cell. Biochem.,99,392-401.
43. Wu, J.D.,Odman, A.,Higgins, L.M.,Haugk, K.,Vessella, R.,Ludwig, D.L.,Plymate, S.R.(2005).In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgendependent and androgen-independent xenograft human prostate tumors.Clin. Cancer Res.,11,3065-3074.
44. Yang, C.C.,Fazli, L.,Loguercio, S.,Zharkikh, I.,Aza-Blanc, P.,Gleave, M.E.,Wolf, D.A.(2015).Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass.Oncotarget,6,22060-22071.
45. Yun, E.J.,Hsieh, J.T.(2014).Cancer stem cell in castration-resistant prostate: altering the adaptation landscape with new therapeutic implication.Adapt. Med.,6,89-94.
46. Zinman, B.,Hoogwerf, B.J.,Durán García, S.,Milton, D.R.,Giaconia, J.M.,Kim, D.D.,Trautmann, M.E.,Brodows, R.G.(2007).The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.Ann. Intern. Med.,146,477-485.
47. Zong, C.S.,Chan, J.,Levy, D.E.,Horvath, C.,Sadowski, H.B.,Wang, L.H.(2000).Mechanism of STAT3 activation by insulin-like growth factor I receptor.J. Biol. Chem.,275,15099-15105.